Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 11/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4209251 | 0.85 | KCNN4 (0.55) | KCNN4ALDH1A1L3MBTL1NPSR1P2RX7 | |
| SCHEMBL4208591 | 0.85 | KCNN4 (0.43) | KCNN4ALDH1A1MAPK1L3MBTL1NPSR1 | |
| SCHEMBL4215231 | 0.85 | KCNN4 (0.42) | KCNN4ALDH1A1MAPK1L3MBTL1NPSR1 | |
| SCHEMBL4212131 | 0.83 | KCNN4 (0.41) | KCNN4ALDH1A1MAPK1L3MBTL1NPSR1 | |
| SCHEMBL4205543 | 0.82 | KCNN4 (0.42) | KCNN4ALDH1A1MAPK1NPSR1MCHR1 | |
| SCHEMBL4205310 | 0.80 | KCNN4 (0.41) | KCNN4ALDH1A1MAPK1NPSR1MCHR1 | |
| SCHEMBL4215375 | 0.80 | MAPK1 (0.57) | KCNN4ALDH1A1MAPK1L3MBTL1P2RX7 | |
| SCHEMBL4209121 | 0.79 | ALDH1A1 (0.45) | KCNN4ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL4211677 | 0.77 | KCNN4 (0.66) | KCNN4ALDH1A1NPSR1 | |
| SCHEMBL4205653 | 0.77 | ALDH1A1 (0.51) | KCNN4ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579480-B2 | Alkoxy-(tetrazol-1-yl)benzaldehyde compound and process for producing the same | TOYO KASEI KOGYO COMPANY LIMITED (JP) | 2009-08-25 | — | — | US | disclosed |
| US-20070060630-A1 | Alkoxy-(tetrazol-1-yl)benzaldehyde compound and process for producing the same | TOYO KASEI KOGYO COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1650198-A1 | ALKOXYTETRAZOL-1-YLBENZALDEHYDE COMPOUND AND PROCESS FOR PRODUCING THE SAME | Toyo Kasei Kogyo Company Limited (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060630-A1 | Alkoxy-(tetrazol-1-yl)benzaldehyde compound and process for producing the same | ALDH7A1, NAT1, ARSA | KCNN4 3193/4885ALDH1A1 4/4885MAPK1 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.